Phio Pharmaceuticals Corp.
PHIO | NASDAQ
$1.01
-$0.02 (-1.94%)
At close: Sep 21, 2026, 4:00 PM ET
$1.02
+$0.01 (+0.99%)
Pre-market:
Sep 22, 2026, 4:00 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 4.62M | 3.64M | 6.33M | 7.01M | 8.89M | 3.72M |
Gross Profit | -4.62M | -3.64M | -6.33M | -7.01M | -8.89M | -3.72M |
Operating Income | -9.22M | -7.39M | -10.82M | -11.46M | -13.51M | -8.79M |
Interest Income | n/a | 231K | n/a | n/a | n/a | n/a |
Pretax Income | -8.7M | -7.15M | -10.83M | -11.48M | -13.29M | -8.79M |
Net Income | -8.7M | -7.15M | -10.83M | -11.48M | -13.29M | -8.79M |
Selling & General & Admin | 4.6M | 3.74M | 4.29M | 4.45M | 4.63M | 5.08M |
Research & Development | 4.62M | 3.64M | 6.33M | 7.01M | 8.89M | 3.72M |
Other Expenses | -4.62M | -3.64M | -6.13M | -7.01M | -8.89M | -3.72M |
Operating Expenses | 4.6M | 3.74M | 4.49M | 4.45M | 4.63M | 5.08M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.22M | 7.39M | 10.82M | 11.46M | 13.51M | 8.79M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 5.98M | 787.47K | 231K | 126.16K | 118.68K | 42.43K |
Shares Outstanding (Diluted) | 5.98M | 787.47K | 231.51K | 126.16K | 118.68K | 42.43K |
EPS (Basic) | -1.45 | -0.91 | -46.87 | -89.61 | -111.32 | -207.25 |
EPS (Diluted) | -1.45 | -0.91 | -46.76 | -89.61 | -111.32 | -207.25 |
EBITDA | -8.7M | -7.15M | -10.64M | -11.41M | -13.21M | -8.72M |
EBIT | -8.7M | -7.15M | -10.83M | -11.48M | -13.29M | -8.79M |
Depreciation & Amortization | 3K | 2K | 184K | 71K | 75K | 72K |
Add to Watchlist
Select watchlists to add or remove PHIO